Editas Medicine Stock Market Value
| EDIT Stock | USD 2.37 0.04 1.66% |
| Symbol | Editas |
Editas Medicine Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Editas Medicine. If investors know Editas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Editas Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.54) | Revenue Per Share 0.752 | Quarterly Revenue Growth (0.99) | Return On Assets (0.34) | Return On Equity (0.79) |
The market value of Editas Medicine is measured differently than its book value, which is the value of Editas that is recorded on the company's balance sheet. Investors also form their own opinion of Editas Medicine's value that differs from its market value or its book value, called intrinsic value, which is Editas Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Editas Medicine's market value can be influenced by many factors that don't directly affect Editas Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Editas Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Editas Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Editas Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Editas Medicine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Editas Medicine's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Editas Medicine.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in Editas Medicine on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding Editas Medicine or generate 0.0% return on investment in Editas Medicine over 30 days. Editas Medicine is related to or competes with Beam Therapeutics, Crispr Therapeutics, Caribou Biosciences, Verve Therapeutics, Intellia Therapeutics, Prime Medicine,, and Vertex Pharmaceuticals. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines t... More
Editas Medicine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Editas Medicine's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Editas Medicine upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 24.4 | |||
| Value At Risk | (6.68) | |||
| Potential Upside | 7.41 |
Editas Medicine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Editas Medicine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Editas Medicine's standard deviation. In reality, there are many statistical measures that can use Editas Medicine historical prices to predict the future Editas Medicine's volatility.| Risk Adjusted Performance | (0.13) | |||
| Jensen Alpha | (0.95) | |||
| Total Risk Alpha | (1.29) | |||
| Treynor Ratio | (0.35) |
Editas Medicine Backtested Returns
Editas Medicine secures Sharpe Ratio (or Efficiency) of -0.17, which denotes the company had a -0.17% return per unit of risk over the last 3 months. Editas Medicine exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Editas Medicine's Mean Deviation of 3.15, standard deviation of 4.16, and Variance of 17.33 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.1, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Editas Medicine will likely underperform. At this point, Editas Medicine has a negative expected return of -0.7%. Please make sure to confirm Editas Medicine's maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Editas Medicine performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.36 |
Below average predictability
Editas Medicine has below average predictability. Overlapping area represents the amount of predictability between Editas Medicine time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Editas Medicine price movement. The serial correlation of 0.36 indicates that just about 36.0% of current Editas Medicine price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Editas Medicine lagged returns against current returns
Autocorrelation, which is Editas Medicine stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Editas Medicine's stock expected returns. We can calculate the autocorrelation of Editas Medicine returns to help us make a trade decision. For example, suppose you find that Editas Medicine has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Editas Medicine regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Editas Medicine stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Editas Medicine stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Editas Medicine stock over time.
Current vs Lagged Prices |
| Timeline |
Editas Medicine Lagged Returns
When evaluating Editas Medicine's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Editas Medicine stock have on its future price. Editas Medicine autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Editas Medicine autocorrelation shows the relationship between Editas Medicine stock current value and its past values and can show if there is a momentum factor associated with investing in Editas Medicine.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.